Skip to content
OpenCapital
Get started

Rigel Pharmaceuticals RIGL Q4 2025 Annual earnings

Reported March 3, 2026 · After market close

Revenue$69.8MBeat by $1.1M
EPS$1.14Miss by $0.19
Revenue estimate$68.7M
EPS estimate$1.33

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$55.3M
EPS estimate$0.13

Financials

Q4 2025

Income statement

See full
Revenue$69.8M+21.2%
Gross profit$63.8M+23.2%
Operating income$23.2M+39.1%
Net income$268.1M+1,769%
EPS (diluted)$14.10+1,641%

Balance sheet

See full
Cash & equivalents$40.6M-28.4%
Total debt$83.5M+29,201%
Total equity$391.5M+11,806%
Total assets$513.6M+213%

Cash flow

See full
Operating cash flow$22.0M+51.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$777.42M+162%
Enterprise value$820.29M+242%
P/E2.1×-14.8×
P/S2.6×+1.0×

Profitability

See full
Gross margin93.3%+3.7pp
Operating margin42.6%+29.1pp
Net margin124.7%+115pp

Returns & leverage

See full
Return on equity185.9%—
Debt / equity0.2×+0.1×
Current ratio2.4×+0.3×

Segments

By product

See full
Gross product sales$84.5M+27.6%
Release Of Share Cost Liability$10.0M—
Delivery of drug supplies, royalties and others$4.1M-41.8%
Discounts and allowances-$19.0M+3.2%

Versus estimates

Revenue

Q1 2026$58.8MMiss by $3.6M
Q4 2025$69.8MBeat by $1.1M
Q3 2025$69.5MBeat by $1.0MQ2 2025$101.7MBeat by $39.4MQ1 2025$53.3MBeat by $5.0MQ4 2024$57.6MIn line

Diluted EPS

Q1 2026$0.44Miss by $0.30
Q4 2025$1.14Miss by $0.19
Q3 2025$1.46Beat by $0.53Q2 2025$3.28Beat by $1.31Q1 2025$0.63Beat by $0.49Q4 2024$0.80Beat by $0.50

Ask the moment Rigel Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Rigel Pharmaceuticals report Q4 2025 earnings?
Rigel Pharmaceuticals (RIGL) reported Q4 2025 earnings on March 3, 2026 after market close.
What were Rigel Pharmaceuticals's Q4 2025 revenue and EPS?
Rigel Pharmaceuticals reported revenue of $69.8M and eps of $1.14 for Q4 2025.
Did Rigel Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $68.7M by $1.1M. EPS missed the consensus estimate of $1.33 by $0.19.
How did Rigel Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 21.2% from $57.6M a year earlier and eps grew 42.5% from $0.80.
Where can I find Rigel Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001034842-26-000016) and the 10-K periodic report (0001034842-26-000015) directly on SEC EDGAR. The filing index links above go to sec.gov.